Your session is about to expire
What is Olumiant
Approved as Treatment by the FDA
Baricitinib, also known as Olumiant, is approved by the FDA for 4 uses including severe, active Rheumatoid arthritis and Tumor Necrosis Factor Inhibitors .Effectiveness
When to interrupt dosage
The proposed measure of Olumiant is contingent upon the determined condition, such as moderate, active Rheumatoid arthritis, Antirheumatic Agents and Mechanical ventilation. Dosage likewise shifts as per the methodology of application featured in the table below.Warnings
Olumiant ContraindicationsOlumiant Novel Uses: Which Conditions Have a Clinical Trial Featuring Olumiant?
74 active trials are now in progress to explore the potential of Olumiant in managing Coronavirus Disease 2019 (COVID‑19), Rheumatoid Arthritis and Hospitalized Patients.Olumiant Reviews: What are patients saying about Olumiant?
Patient Q&A Section about olumiant
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is Olumiant approved for alopecia?
"The FDA has approved Olumiant for the treatment of severe alopecia areata. Olumiant is a once-daily pill that is taken orally."
What kind of drug is Olumiant?
"The drug Baricitinib, also known as Olumiant, is used to treat rheumatoid arthritis by blocking the action of Janus kinase enzymes which are involved in the inflammation that causes the symptoms of rheumatoid arthritis."
What is Olumiant medication for?
"Olumiant (baricitinib) is a medicine that needs a prescription from a doctor. It is used to treat adults with arthritis that is moderately to severely active. This is after treatment with 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, but did not work well enough or were not tolerated."
What is Olumiant 4 mg used for?
"There are recessed areas on each side of the tablets. Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs."